ENROX 100 MG/ML ORAL SOLUTION

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

ENROFLOXACIN

제공처:

Krka, d.d., Novo mesto

ATC 코드:

QJ01MA90

INN (International Name):

ENROFLOXACIN

복용량:

100 Mg/Ml

약제 형태:

Oral Solution

처방전 유형:

POM

치료 그룹:

Fowl - Chicken, Fowl - Turkey

치료 영역:

Enrofloxacin

치료 징후:

Antibacterial

승인 상태:

Authorised

승인 날짜:

2008-06-20

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Enrox 100 mg/ml oral solution.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Oral solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Chickens (broilers, broiler breeders, replacement chickens), turkeys.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections caused by the following bacteria susceptible to enrofloxacin:
CHICKENS
_Mycoplasma gallisepticum,_
_Mycoplasma synoviae,_
_Avibacterium paragallinarum,_
_Pasteurella multocida,_
_Escherichia coli._
TURKEYS
_Mycoplasma gallisepticum,_
_Mycoplasma synoviae,_
_Pasteurella multocida,_
_Escherichia coli._
4.3 CONTRAINDICATIONS
Do not use for prophylaxis.
Do not use when resistance / cross-resistance to (fluoro)quinolones is known to occur in the flock
intended for treatment.
Do not use in poultry producing eggs for human consumption.
Do not use in aquatic poultry.
Do not use in infections caused by _Streptococcus _spp., because of only marginal susceptibility to enrofloxacin.
ACTIVE SUBSTANCE
1 ml of oral solution contains:
Enrofloxacin
100 mg.
EXCIPIENTS
Benzyl alcohol
14 mg.
For the full list of excipients, see section 6.1
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 02/04/2015_
_CRN 7020279_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Treatment of _Mycoplasma _spp. infections may not eradicate the organism.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Official and local antimicrobial policies should be taken into account when the product is used.
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to
respond poorly, to other c